Investors Investors

Stock Quote

Stock Quote

6:50 PM EDT on Mar 21

Press Releases

Press Releases

All Releases
Mar 14, 2019
AZEDRA ® (iobenguane I 131) U.S. Commercial Launch – 14 Treatment Requests from Patients Have Been Received and Scheduling for those Patients is Underway; 8 Centers Throughout the U.S. are Ready to Treat Patients Advancing Lifecycle Initiatives for AZEDRA in Additional MIBG-Avid Tumor Indications
Mar 14, 2019
NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it has asserted
Mar 11, 2019
NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that safety data from a pooled analysis of all available clinical trial
Mar 07, 2019
NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that it will host a conference call and webcast to review fourth quarter
Feb 11, 2019
NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that it has acquired the Somerset, NJ manufacturing facility for AZEDRA ®
Jan 03, 2019
Accelerates European Development of PSMA-Targeted Imaging Agent with Global Leader in Nuclear Medicine NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and
Jan 02, 2019
NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced the appointment of Asha Das, M.D.
Dec 03, 2018
-Potential to Improve Early Detection and Transform the Treatment Landscape for Recurrent Prostate Cancer - NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting
Nov 19, 2018
NEW YORK, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that safety and tolerability data from a pooled analysis of four
Nov 08, 2018
AZEDRA ® (iobenguane I 131) Approved by U.S. Food and Drug Administration (FDA) AZEDRA U.S. Launch Progressing and AZEDRA Added to the NCCN Guidelines and Four CMS-Recognized Drug Compendia Phase 3 Study of PyL TM for the Detection of Biochemical Recurrence of Prostate Cancer to Begin by Year End
Nov 06, 2018
NEW YORK, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that management will present at the following upcoming investor
Nov 01, 2018
NEW YORK , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that it will host a conference call and webcast to review the third
Oct 11, 2018
– Trial will utilize PyL imaging in order to target the patients most likely to benefit, advancing the Company’s theranostic approach to the treatment of prostate cancer – NEW YORK, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing
Oct 09, 2018
NEW YORK, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that the Company’s pivotal trial of AZEDRA ®  (iobenguane I 131), the
Oct 05, 2018
-PyL highly sensitive, 93-99%, in reliably detecting  metastatic prostate cancer lesions and highly specific, 96-99%, in confirming the absence of pelvic lymph node disease - -Study data highlights the strong positive predictive values of PyL to detect prostate cancer in pelvic lymph nodes and
Sep 25, 2018
NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that Mark R. Baker, Chief Executive Officer, will present at the Cantor
Sep 17, 2018

NEW YORK, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that AZEDRA ® (iobenguane I 131), the Company’s radiotherapeutic, has

Sep 12, 2018

-Meets Co-Primary Endpoint of Specificity; 1404 Successfully Identifies Patients Without Clinically Significant Prostate Cancer- -Co-Primary Endpoint of Sensitivity to Identify Patients with Clinically Significant Disease Not Met- NEW YORK, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Progenics

Aug 08, 2018

NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today the pricing of an underwritten public offering of 9,090,909 primary shares of its common stock at a public offering price of $8.25 per share. The gross proceeds from the sale of the primary

Aug 07, 2018

NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today that it is offering to sell shares of its common stock in an underwritten public offering pursuant to an effective shelf registration statement.